Neuronal nicotinic acetylcholine receptors (nAChRs) expressed on mesostriatal dopaminergic neurons are thought to mediate several behavioral effects of nicotine, including locomotion, habit learning, and reinforcement. Using immunoprecipitation and ligand-binding techniques, we have shown that both ␣6␤2* and ␣4(non␣6)␤2* nAChRs are expressed in the caudate-putamen and that only ␣6* nAChRs can bind ␣-conotoxin MII and methyllycaconitine with affinities of 1.3 and 40 nM, respectively. Further studies performed on 6-hydroxydopamine-lesioned striatum led to the identification of nAChR subtypes selectively expressed on dopaminergic terminals [␣4␣5␤2, ␣4␣6␤2(␤3), and ␣6␤2(␤3)], nondopaminergic neuronal structures (␣2␣4␤2), or both structures (␣4␤2). The identification of the nAChRs expressed on striatal dopaminergic terminals opens up the possibility of developing selective nAChR ligands active on dopaminergic systems and associated diseases, such as Parkinson's disease.
The mesostriatal dopamine (DA) pathway is a major brain target for nicotinic agonists. Its ventral (the mesolimbic DA pathway) and dorsal (the nigrostriatal DA pathway) components both express high levels of nicotinic acetylcholine receptors (nAChRs), which are thought to mediate several behavioral effects of nicotinic agonists (including the modulation of locomotor activity, reinforcement, and habit learning) (Di Chiara, 2000) .
Neuronal nAChRs comprise a heterogeneous family of pentameric oligomers made up of combinations of subunits encoded by at least 11 different genes in mammals. They have been grouped into two subfamilies based on their phylogenetic, functional, and pharmacological properties (Le Novére and Changeux, 1995; Corringer et al., 2000) , namely the ␣-bungarotoxin (␣-Bgtx)-sensitive or homomeric nAChRs (␣7 subunit), and the ␣-Bgtx-insensitive or heteromeric nAChRs (␣2-␣6 and ␤2-␤4 subunits). These latter subunits can combine to form a number of functionally and pharmacologically different heteropentamers consisting of two, three, or four different subunits.
In situ hybridization and single-cell PCR studies have shown that 80 -100% of midbrain DA neurons express ␣4, ␣5, ␣6, ␤2, and ␤3 subunits, 40 -60% express ␣3 and ␣7, and a few of them express ␤4 (Le Novère et al., 1996; Klink et al., 2001; Azam et al., 2002) . A large number of heteromeric nAChR subtypes are therefore potentially present in these neurons. Previous studies using ␣-conotoxin MII (␣-CntxMII, an antagonist selective for ␣3␤2 or ␣6␤2 interfaces) (Cartier et al., 1996; Champtiaux et al., 2002; Kuryatov et al., 2002) and knock-out (KO) mice lacking specific nAChR subunits have suggested the existence of at least two main receptor populations containing ␣4␤2 or ␣6␤2 subunits Zoli et al., 1998; Klink et al., 2001; Champtiaux et al., 2002) .
Using a combination of techniques (immunoprecipitation and purification of native nAChRs, followed by their pharmacological characterization in intact or DA denervated striatum), we have established the composition of nAChRs expressed in striatal DA projections and in nondopaminergic neuronal structures.
MATERIALS AND METHODS
Animals and materials. Adult male pathogen-free Sprague Dawley rats (Harlan-Nossan, Milan, Italy) were used. All animal experimentation was conducted in accordance with the European Communities Council Directive of 24 November 1986 (86/609/ EEC). (ϩ/Ϫ) 3 ⌯-epibatidine (Epi; specific activity, 50 -66 C i /mmol) was purchased from Amersham Biosciences (Arlington Heights, IL), 125 I-Epi (s.a. 2200 C i /mmol) and 3 H-W I N35,428 (s.a. 86 C i /mmol) from N EN (Boston, M A), and nonradioactive ligands were purchased from Sigma (St. L ouis, MO). ␣-C ntxM II was synthesized as described previously (C artier et al., 1996) .
Antibody production and characterization. The polyclonal antibodies against the ␣2, ␣3, ␣4, ␣5, ␣6, ␤2, ␤3, and ␤4 nAChR subunits were produced in rabbit as previously described (Vailati et al., 1999) and affinity purified. The peptides obtained from rat or human sequences were located in the putative cytoplasmic loop between M3 and M4 and /or at the C OOH terminal. For almost all of the subunits we raised antisera directed against two separate peptides of the same subunit, and the immunoprecipitation values reported are the mean of results obtained using both antisera. The affinity-purified antisera were bound to cyanogen bromide-activated Sepharose at a concentration of 1 mg /ml, and the columns were used for subtype immunopurification.
Characterization of antibody specificit y. The antisera were tested by quantitative immunoprecipitation experiments on 2 nM 3 H-Epi-labeled nAChRs present in 2% Triton X-100 extracts prepared from brain membranes and /or immunopurified nAChRs. Because 3 H-Epi binds ␣7* nAChRs, albeit with nanomolar affinity, we always preincubated the membranes and 2% Triton X-100 extracts with 2 M ␣-Bgtx. Only the receptors labeled with 3 H-Epi were immunoprecipitated, which assured the specificity of the quantification. The antisera were tested in available wild-type (W T) and KO mice (immunoprecipitation expressed as percentage of 3 H-Epi-labeled receptors in total brain): 60 and 1% (anti-␣4 antisera), 11 and 0% (anti-␣5 antiserum), 84 and 2% (anti-␤2 antisera). Anti-␣6 and anti-␤3 antisera immunoprecipitated 25 Ϯ 1 versus 1 Ϯ 0.3% and 8 Ϯ 2 versus 2 Ϯ 1%, respectively, of 3 H-Epi-labeled striatal receptors in ␣6 W T versus KO mice (N. Champtiaux and C. Gotti et al., unpublished observations) . Anti-␣2, -␣4, and -␤2 antisera immunoprecipitated at ϳ0, 80, and 90%, respectively, of ␣4␤2 or ␣4␣5␤2 receptors immunopurified from rat cortex, whereas anti-␣5 antisera immunoprecipitated 1% of the ␣4␤2 receptors but 75% of the ␣4␣5␤2 receptors. Anti-␣3 and -␤4 antisera immunoprecipitated only 1-2% of cortical ␣4␤2 and ␣4␣5␤2 receptors but immunoprecipitated 74 and 70%, respectively, of 3 H-Epi-labeled receptors from rat superior cervical ganglion. Finally, anti-␣2 antisera immunoprecipitated up to 27% of ␣2␣5␤2 purified from postnatal rat retina (M. Moretti, unpublished observations).
Binding assay and pharmacolog ical e xperiments. Binding techniques for solubilized or immunoimmobilized nAChRs, receptor immobilization by anti-subunit-specific antisera, and immunoprecipitation of 3 H-Epilabeled receptors by anti-subunit specific antisera were performed as in Vailati et al. (1999) . The affinity-purified anti-␣6 or anti-␤2 antisera were bound to microwells (Maxi-Sorp; Nunc, Roskilde, Denmark) and then incubated overnight at 4°C with 200 l of 2% Triton X-100 total (␣6 microwells) or ␣6 subunit-depleted (␤2 microwells) striatal extract containing 10 -30 fmol of receptors. We ascertained that 84 Ϯ 2% of 3 H-Epi binding could be solubilized from striatal membranes using 2% Triton X-100.
Receptor subt ype immunopurification. For each purification experiment the caudate -putamen from 20 -30 animals was dissected, immediately frozen at Ϫ70°C, and processed as described in Del Signore et al. (2002) . The extract was incubated three times with 5 ml of Sepharose-4B bound anti-␣6 antisera to remove the ␣6 receptors. The flow-through of the ␣6 column was reincubated with 5 ml of Sepharose-4B with bound anti-␣4 or ␤2 antisera. The bound receptors were eluted by competition with 100 M of the corresponding ␣6, ␣4, or ␤2 peptide used for antiserum production.
6-hydroxydopamine lesion and 3 H-W IN 35,428 binding. Unilateral DA denervation of striatum was performed by injecting the selective DA neurotoxin 6-hydroxydopamine (6-OH DA) in the medial forebrain bundle. The animals were deeply anesthetized with halothane, and 6-OH DA (10 g/4 l) was injected (coordinates: anterior, Ϫ4 mm; lateral, 1.8 mm, dorsal, Ϫ7.5 mm) using a 10 l Hamilton syringe (26G) during 4 min, waiting 2 min before withdrawal of the needle. The animals were killed 14 d after the lesion. The extent of DA denervation was assessed by W I N35,428 binding, a ligand for DA transporter that is selectively localized on DA terminals. In preliminary experiments the affinity of 3 H-W I N35,428 was determined using established protocols (K immel et al., 2000) .
3 H-W I N35,428 binding was determined individually in striata from 30 control and 30 6-OH DA-lesioned rats using a saturating concentration of 100 nM 3 H-W I N35,428 in the presence or absence of 10 M GBR 12935. 6-OH DA-lesioned striata with a decrease of 3 H-W I N35,428 Ͻ80% were discarded.
RESULTS

Overall subunit composition of nicotinic receptors in striatum
Because the contribution of ␣7* nAChR to nicotine effects on striatum is still debated , we first determined the amount of ␣7* versus (non␣7)* nAChRs in striatal homogenates. We found that 125 I-␣〉gtx binding is Ͻ3% of 3 H-Epi binding (4.7 Ϯ 1.6 fmol/mg of protein vs 153.7 Ϯ 15.0 fmol/mg of protein, respectively).
We next determined the overall subunit composition of striatal nAChRs by studying 3 H-Epi-labeled receptors immunoprecipitated by subunit-specific antisera. Almost all of the receptors (90.7%) contained the ␤2 subunit, whereas ␣4 (69.0%) and ␣6 (19.3%) appeared to be the most represented ␣ subunits. We also found that a considerable percentage of 3 H-Epi-labeled receptors contain ␣5 (18.7) or ␤3 (8.9%) subunits. Instead, the level of ␣2, ␣3, and ␤4 subunits was low (3.9, 3.3, and 1.3%, respectively).
These results show that ␣6␤2* and ␣4␤2* are the main nAChR populations present in rat striatum, whereas putative ␣3␤2* nAChRs, previously proposed as a major striatal subtype (Kulak et al., 1997; Kaiser et al., 1998) , are almost absent from this region.
Subunit composition of striatal ␣6␤2* subtypes
To isolate ␣6␤2* receptors, we immunodepleted the striatal extract of ␣6* receptors by using an affinity column bearing anti-␣6 antisera. Selective ␣6-containing nAChR immunodepletion was confirmed by the fact that immunoprecipitated ␣6-containing 3 H-Epi-labeled receptors decreased from 19.3% in the total striatal extract to 2.9% in the flow-through of the ␣6 column. In addition, ␣4-containing and ␣5-containing receptors increased (from 69.0 to 87.6% and from 18.7 to 21.8%, respectively), ␤2-containing receptors remained unchanged, and ␤3-containing receptors markedly decreased (from 8.9 to 1.2%). Indeed, the increase in ␣4 subunit in the flow-through demonstrates that the majority of the ␣4 subunit pool is not assembled with ␣6 subunit.
To identify the subunit composition of the ␣6-containing receptors, we eluted them from the affinity column with the ␣6 peptide, and then labeled with 3 H-Epi and immunoprecipitated the eluate with subunit specific antisera (Fig. 1) . The anti-␣4, ␤2 and ␤3 antisera immunoprecipitated 37.8, 87.9, and 19.7%, respectively, of the purified 3 H-Epi-labeled ␣6-containing receptors. The anti-␣2, ␣3, ␣5, and ␤4 antisera immunoprecipitated only 0.1, 0, 2.1, and 2.6%, respectively, of the purified ␣6-containing receptors.
These immunoprecipitation results indicate that purified ␣6␤2* receptor population is a mixture of two main subtypes, namely ␣6␤2 and ␣4␣6␤2 nAChRs, some of which also contain the ␤3 subunit.
Subunit composition of striatal ␣4(non␣6)␤2* subtypes
To determine the subunit composition of ␣4␤2* receptor population that do not contain the ␣6 subunit (␣4(non␣6)␤2*), we immunopurified nAChRs present in the flow-through of the ␣6 column over an anti-␣4 column, eluted using the ␣4 peptide, and performed an immunoprecipitation with subunit-specific antisera (Fig. 1) . The anti-␣4, -␣5, and -␤2 antisera immunoprecipitated 84, 21, and 82%, respectively, of 3 H-Epi-labeled receptors recovered using this method, whereas the anti-␣2, -␣3, -␣6, -␤3, and -␤4 immunoprecipitated 7.4, 2.5, 0.9, 2.5, and 1.6%, respectively, of the purified eluate (Fig. 1) . The subunit content of these ␣4* nAChRs was identical to that obtained by passing the ␣6 flowthrough over an anti-␤2 column to immunopurify nAChRs (data not shown) and very similar to that determined in the flowthrough of the ␣6 column (see above), indicating that no other main nAChR receptor populations are present in striatum besides ␣6␤2* and ␣4(non␣6)␤2*.
These immunoprecipitation results show that ␣4(non␣6)␤2* nAChRs comprise ␣4␤2 and ␣4␣5␤2 subtypes with a minor proportion of the ␣2␣4␤2 subtype.
Pharmacological profile of striatal ␣6␤2* and ␣4(non␣6)␤2* nAChRs To explore the pharmacology of the two receptor populations, we immunoimmobilized the ␣6␤2* receptors using an anti-␣6 column and compared their pharmacological profile with that of the ␣4(non␣6)␤2* receptors immobilized over an anti-␤2 column.
Equilibrium binding assays revealed no significant differences in the affinity for 3 H-Epi of the ␣6␤2* and ␣4non␣6␤2* receptor populations [apparent K d value of 34 pM (coefficient of variation, 34%) and 41 pM (coefficient of variation, 25%) for ␣6␤2* and ␣4(non␣6)␤2* receptors, respectively]. We then performed competition binding studies using a number of nicotinic ligands. Although no significant difference was detected for the agonists acetylcholine, nicotine, and cytisine and the antagonists dihydro-␤-erythroidine and D-tubocurarine (Fig. 2a,b) , significant differences were observed for ␣-CntxMII and methyllycaconitine (MLA). Both ligands showed a statistically significant better fit for a two-site model with a high-and a low-affinity site when tested on the ␣6␤2* nAChRs. ␣-CntxMII had a high affinity site for ␣6-containing nAChRs with a K i of 1.3 nM and a site with no or low affinity with a K i Ͼ10 M (Fig. 2c, Table 1 ), whereas MLA had a high-affinity site with a K i of 40 nM and a low-affinity site with a K i of 20.8 M (Fig. 2d, Table 1 ). On the other hand, for ␣4(non␣6)␤2* receptors, both ligands showed the presence of only a single class of low-affinity sites with a K i of Ͼ10 M for ␣-CntxMII and a K i of 25 M for MLA.
Nicotinic receptor subtypes expressed on striatal dopaminergic terminals
Several neuronal structures in striatum in addition to nigrostriatal dopaminergic terminals express nAChRs . To distinguish nAChR subtypes expressed by dopaminergic and nondopaminergic structures, we performed striatal DA denervation using the neurotoxin 6-OHDA. In view of the very low density of noradrenergic terminals in striatum, this technique allows a selective destruction of DA terminals. The extent of the denervation was ϳ85%, as assessed by binding to 3 H-WIN35,428 (Fig. 3a) .
We first examined the effect of DA denervation on the amount of 3 H-Epi binding, showing a decrease by ϳ50% in 6-OHDAlesioned striata (183 Ϯ 10 and 99 Ϯ 6 fmol/mg protein in intact vs lesioned striatum) (Fig. 3b) .
We then assessed the nAChR subunit composition of 3 H-Epilabeled receptors of control and 6-OHDA-lesioned striata in quantitative immunoprecipitation experiments (Fig. 3c) . These experiments revealed an almost complete disappearance of nAChRs containing the ␣5 (84%), ␣6 (87%), or ␤3 (73%) subunits, which matches very closely the reduction in DA innervation, a marked but partial reduction of the receptors containing ␣4 (42%) and ␤2 (50%) subunits, whereas the other subunits were unchanged. These results demonstrate that ␣6, ␣5, and ␤3 subunits are selectively enriched in DA terminals, ␣4 and ␤2 subunits are present in both dopaminergic and nondopaminergic cells, and ␣2 subunit is only present in nondopaminergic cells.
Combining the results obtained on DA-denervated striata with those obtained on immunopurified receptors, it can be concluded that striatal DA terminals express ␣6␤2 and ␣6␣4␤2 (with or (18) 25,000 (23) K d and K i values were derived from curves of 125 I-Epi saturation and competition binding, respectively, to ␣6␤2* or ␣4(non␣6)␤2* immunoimmobilized receptors. Curves obtained from three or four separate experiments were fitted using a nonlinear least-squares analysis program. For both ␣-conotoxin MII and methyllycaconitine, a two-site model was statistically significant (F test), whereas for D-tubocurarine and cytisine the data were better fitted with a one-site model. Numbers in parentheses represent percentage of coefficient of variation.
without ␤3 subunit) as well ␣4␣5␤2 and ␣4␤2 nAChR subtypes, whereas nondopaminergic striatal structures express ␣4␤2 and ␣2␣4␤2 nAChR subtypes.
DISCUSSION
In this study, we identified the major nAChR subtypes expressed in dopaminergic terminals and nondopaminergic neuronal structures in the caudate-putamen at the molecular and pharmacological level. Much information about native nAChRs in the brain and ganglia has been obtained using immunopurification and immunoprecipitation techniques (for review, see Lindstrom 2000) . Our identification of striatal nAChR subtypes relied on the use of a series of antisera raised against unique amino acid sequences of the different subunits. To obtain a quantitative evaluation of the subunit composition of a receptor subtype, it is necessary to evaluate the efficiency of the immunoprecipitation of antigens by their respective antisera. This was assessed for the ␣3, ␣4, ␣5, ␣6, ␤2, and ␤4 subunits, and ranged from 75 to 90%, thus suggesting that the values obtained in this study are probably slightly underestimated. A second caveat concerns the detection limits of the immunoprecipitation and immunopurification techniques and so, in the following discussion, we will not consider the contribution to receptor composition of subunits that were immunodetected in amounts Ͻ3%; therefore, this means that the existence of minor nAChR subtypes (Ͻ3-5%) may be overlooked. Finally, it must be considered that possible changes in nAChRs expressed on DAceptive neurons induced by DA denervation cannot be presently excluded.
In defining the striatal nAChR subtypes, we followed the current hypothesis that heteromeric nAChRs have at least two subunits bearing the principal amino acid loops for ACh binding interfaces (i.e., ␣2, ␣3, ␣4, or ␣6 subunits) and two subunits bearing the complementary amino acid loops for ACh binding interfaces (i.e., ␤2 or ␤4 subunits), whereas the fifth subunit can be either a complementary subunit or a purely structural subunit (␣5 or ␤3 subunits) (Corringer et al., 2000) .
Striatal ␣6␤2* and ␣4(non␣6)␤2* nAChRs have a partially different pharmacology Present immunopurification approach allowed to isolate two populations of striatal nAChRs: one contains ␣4␤2*, but not ␣6, subunits and accounts for ϳ70% of the nAChRs; the other contains ␣6␤2* subunits and accounts for ϳ20%. Furthermore, whereas ␣6␤2* nAChRs are selectively expressed on dopaminergic terminals (see below), ␣4(non␣6)␤2* nAChRs are expressed on both dopaminergic terminals and nondopaminergic cells. These two populations have indistinguishable binding affinity for several classical nicotinic agonists and antagonists, including acetylcholine, nicotine, cytisine, dihydro-␤-erythroidine and D-tubocurarine. However, the antagonists ␣-CntxMII and MLA could discriminate the two receptor populations by showing low (micromolar) affinity for the ␣4(non␣6)␤2*, but both low (micromolar) and high (nanomolar) affinity for the ␣6␤2* receptors. Because a subset of ϳ40% of the ␣6␤2* nAChRs also contain the ␣4 subunit (Fig. 1a ) (see below for discussion), we hypothesize that both compounds bind an ␣6␤2 interface (exclusively present in ␣6␤2*) with nanomolar affinity (Vailati et al., 1999; Barabino et al., 2001; Champtiaux et al., 2002) and an ␣4␤2 interface [present in both ␣6␤2* and ␣4(non␣6)␤2* nAChRs] with micromolar affinity.
Based on pharmacological studies using ␣-CntxMII (Kulak et al., 1997; Kaiser et al., 1998) , neuronal Bgtx (Grady et al., 1992) , and UB-165 (Sharples et al., 2000) on striatal synaptosomal preparations, it was suggested that both ␣4* and (non␣4)* nAChRs mediate DA release in striatum. (Non␣4)* nAChRs were identified as ␣3* nAChRs on the basis of the high affinity of ␣-CntxMII for ␣3␤2* nAChRs expressed in reconstituted systems (Cartier et al., 1996) . However, subsequent studies showed that ␣-CntxMII binds and blocks native ␣6* nAChRs (Vailati et al., 1999; Barabino et al., 2001; Kuryatov et al., 2002) , and equilibrium-binding experiments in KO mice showed that ␣-CntxMII binding disappears from the striatum of ␣6Ϫ/Ϫ (Champtiaux et al., 2002) but not from ␣3Ϫ/Ϫ mice (Whiteaker et al., 2002) . The present study unequivocally shows that ␣-CntxMII binds with high affinity to immunopurified native ␣6␤2* nAChRs and that ␣6* nAChRs constitute the major (non␣4)* nAChR in this brain region as only negligible amounts of other ACh binding subunits (including the ␣3 subunit)were detected in striatum.
Both striatal ␣6␤2* and ␣4(non␣6)␤2* nAChR populations are heterogeneous and differentially expressed by dopaminergic and nondopaminergic neurons Our immunoprecipitation studies of immunopurified native receptors showed that ␣6␤2* nAChRs are heterogeneous and consist of two main subpopulations of roughly equal size (i.e., ␣6␤2 and ␣4␣6␤2 nAChRs) with a portion (20%) also containing the ␤3 subunit. ␣4(non␣6)␤2* nAChRs are also heterogeneous and form a large population (60 -70%) of (␣4)2(␤2)3 nAChRs, a considerable population (20%) of (␣4)2␣5(␤2)2 nAChRs, and a minor population (5%) of ␣2␣4␤2* nAChRs.
One interesting result is that the structural subunits ␣5 and ␤3 always coassemble with the ␣4 and ␣6 subunit, respectively. This selective assembly fits very nicely with previous in situ hybridization studies, showing that ␣6 and ␤3 subunit mRNAs are always coexpressed throughout brain nuclei (Le Novére et al., 1996) and that ␣5 mRNA is present only in ␣4 mRNA-containing neurons. However, it must be noted that the case for selective coexpression of the ␣4 and ␣5 subunits is not strong, because ␣4 subunit mRNA is expressed by most neuronal populations (but see the case of the medial habenula for a strict similarity between the subnuclear pattern of ␣5 and ␣4 mRNAs; Le Novère et al., 1996) . Nothwithstanding the fact that the functional role of ␣5 and ␤3 remains difficult to assess, the strict regulation of their assembly suggests that they may subserve an important role in nAChR subtype physiology, including a change in their electrophysiological features, turnover, and/or subcellular targeting.
On the basis of the changes in subunit content observed in DA-denervated striata, it can indeed be concluded that although (␣4)2(␤2)3ϭ(␣4) 2 (␤2) 3 nAChRs are expressed by both dopaminergic and nondopaminergic cell types, ␣6␤2, ␣4␣6␤2, and (␣4)2␣5(␤2)2ϭ(␣4) 2 ␣5(␤2) 2 nAChRs are expressed only on dopaminergic terminals, and ␣2␣4␤2 nAChRs are expressed only by nondopaminergic cell types. Because DA denervation decreases striatal 3 H-Epi binding by ϳ50%, it can be inferred that dopaminergic terminals express four major populations of nAChRs: (␣4)2(␤2)3ϭ(␣4) 2 (␤2) 3 (ϳ30%), (␣4)2␣5(␤2)2ϭ(␣4) 2 ␣5(␤2) 2 (ϳ30%), ␣6␤2(␤3) (ϳ25%), and ␣4␣6␤2(␤3) (ϳ15%). These results agree well with those of in situ hybridization and singlecell PCR studies of midbrain DA neurons (Le Novère et al., 1996; Klink et al., 2001; Azam et al., 2002) , which showed that ␣4, ␣5, ␣6, ␤2, and ␤3 mRNAs are expressed by the vast majority of DA neurons at moderate to high levels, whereas ␣3 and ␤4 mRNAs are detected in a more restricted number of neurons and at low levels. They are also in line with the evidence of ␤2 subunit immunoreactivity in rat nigrostriatal DA terminals (Jones et al., 2001) , as well as with studies showing that selective lesion of the nigrostriatal pathway in monkey leads to a complete loss of high affinity ␣-CntxMII binding (i.e., ␣6␤2* nAChRs) and a 50% reduction in 125 I-Epi binding in striatum (Kulak et al., 2002) . The mesostriatal dopamine pathway plays an essential role in locomotion, movement coordination, habit learning, and reinforcement and is known to be modulated by nicotinic agents. In particular, recent studies have shown that striatal DA release is physiologically regulated by cholinergic tone through nAChRs activation (Zhou et al., 2001) . A pathophysiological role of nAChRs in this neuronal system has been proposed on the basis of evidence of a negative correlation between cigarette smoking and the incidence of Parkinson's disease, the protective effects of nicotine treatment against nigrostriatal DA pathway degeneration in animal models of Parkinson's disease (Quik and Jeyarasasingam, 2000) . The identification of the different nAChR subtypes expressed by DA terminals and the demonstration that some subtypes are only expressed by DA structures opens up the possibility of developing ligands selectively acting on the release of dopamine from striatal terminals.
